Qlife Holding AB (publ) (“Qlife” or the “Company”) has decided to withdraw its proposal to change the Company’s name as the intended name, Egoo Health AB, cannot be registered by the Swedish Companies Registration Office (Bolagsverket).
On 29 August 2024, Qlife announced its intention to change the Company’s name to Egoo Health AB as part of a broader rebranding initiative. However, the Swedish Companies Registration Office has informed the Company that Egoo Health AB cannot be registered. As a result, Qlife has decided to withdraw the proposal to change its name.
The Company remains fully dedicated to its business strategy and operations. This decision will have no impact on its operations, nor on its relationships with customers, partners, or stakeholders.
“It was not possible to streamline into one name, however it won’t have any effect on the positive journey we have started in the rare disease field with launch of our PHE test and with our continued focus on advancing our effort in China”, says Thomas Warthoe CEO of Qlife.
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
About Qlife
Qlife is a medical technology company that aims to revolutionise the market for clinical whole blood biomarker testing. By making it possible to perform tests at home instead of in the hospital, access to blood samples is facilitated, which can promote monitoring of important parameters and contribute to better treatment. The company’s share (QLIFE) is traded on Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser (e-mail: ca@gwkapital.se).
Read more at Egoo.health, Qlifeholding.com or follow us on LinkedIn.
